|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 950 F Street, NW |
Address2 | Suite 300 |
City | Washington |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 31350-12
|
||||||||
|
6. House ID# 306540000
|
TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Paul J. Larsen - Assistant General Counsel |
Date | 04/21/2008 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.Con.Res. 312, Budget Resolution FY 2009: FDA, HHS and CMS budget issues, importation, non-interference
S.Con.Res. 70, Budget Resolution FY 2009: FDA, HHS and CMS budget issues, importation, non-interference
Preparation for FY 2009 Agriculture Appropriations including FDA budget and importation issues (no bill introduced yet)
Preparation for FY 2009 Labor HHS Appropriations including HHS budget, importation, comparative effectiveness, and Medicare Part D issues (no bill introduced yet)
Preparation for FY 2009 Department of Homeland Security Appropriations including importation issues (no bill introduced yet)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Richard |
Smith |
|
|
|
Steve |
Tilton |
|
|
|
Amy |
Efantis |
|
Legislative Director - Rep. Artur Davis |
|
Bryant |
Hall |
|
|
|
Valerie |
Jewett |
|
Legislative Director - Rep. Rodney Frelinghuysen |
|
Brian |
Nagle |
|
|
|
Matt |
Sulkala |
|
Senior Legislative Assistant - Rep. Allen Boyd |
|
Derrick |
White |
|
|
|
Billy |
Tauzin |
|
|
|
Maya |
Bermingham |
|
|
|
Randy |
Burkholder |
|
|
|
Kendra |
Martello |
|
|
|
Byron |
Patterson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 1902, Protecting Consumer Access to Generic Drugs Act of 2007: patent settlements
H.R. 1908, Patent Reform Act of 2007: patent issues
S. 1145, Patent Reform Act of 2007: patent issues
S. 316, Preserve Access to Affordable Generics Act: patent settlements
Preparation for Senate reauthorization of the Federal Trade Commission (no bill introduced yet)
International intellectual property issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Patent & Trademark Office (PTO), U.S. Trade Representative (USTR), Natl Economic Council (NEC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Korn |
|
|
|
Brian |
Toohey |
|
|
|
Richard |
Smith |
|
|
|
Alan |
Gilbert |
|
|
|
Steve |
Tilton |
|
|
|
Bryant |
Hall |
|
|
|
Robert |
Filippone |
|
|
|
Hallie |
Maranchick |
|
|
|
Heather |
Strawn |
|
|
|
Derrick |
White |
|
|
|
Billy |
Tauzin |
|
|
|
Mimi |
Kneuer |
|
|
|
Byron |
Patterson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 380, Pharmaceutical Market Access and Drug Safety Act of 2007: importation
H.R. 1038, Access to Life-Saving Medicine Act: follow-on biologics
H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007: follow-on biologics
H.R. 3610, Food and Drug Import Safety Act of 2007: import safety
H.R. 5501, Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008: public health
H.R. 5629, Pathway for Biosimilars Act: follow-on biologics
S. 242, Pharmaceutical Market Access and Drug Safety Act of 2007: importation
S. 334, Healthy Americans Act: non-interference
S. 623, Access to Life-Saving Medicine Act: follow-on biologics
S. 1693, Wired for Health Care Quality Act: health care and technology
S. 2663, CPSC Reform Act: importation
S. 2731, Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008: access and public health
Measures to mitigate BSE risks related to non-ambulatory cattle
Pharmaceuticals in the environment issues
Anti-counterfeiting issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Korn |
|
|
|
Richard |
Smith |
|
|
|
Lauryl |
Jackson |
|
|
|
Alan |
Gilbert |
|
|
|
Steve |
Tilton |
|
|
|
Amy |
Efantis |
|
Legislative Director - Rep. Artur Davis |
|
Bryant |
Hall |
|
|
|
Hallie |
Maranchick |
|
|
|
Brian |
Nagle |
|
|
|
Heather |
Strawn |
|
|
|
Matt |
Sulkala |
|
Senior Legislative Assistant - Rep. Allen Boyd |
|
Derrick |
White |
|
|
|
Billy |
Tauzin |
|
|
|
Mimi |
Kneuer |
|
|
|
Maya |
Bermingham |
|
|
|
Randy |
Burkholder |
|
|
|
Kendra |
Martello |
|
|
|
Byron |
Patterson |
|
|
|
Marjorie |
Powell |
|
|
|
Lori |
Reilly |
|
|
|
Jennifer |
Van Meter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 1424, Paul Wellstone Mental Health and Addiction Equity Act of 2007: Medicaid rebate
H.R. 3162, Children's Health and Medicare Protection Act of 2007: Medicaid rebate
H.R. 5605, Physician Payments Sunshine Act of 2008: transparency issues
S. 558, Mental Health Parity Act of 2007: health insurance issues
S. 2029, Physician Payments Sunshine Act of 2007: transparency issues
S. 2041, False Claims Act Correction Act of 2007: liability issues
Medicaid Program; Prescription Drugs; Final Rule, 72 Fed. Reg 39142 (July 17, 2007) (AMP Rule): Medicaid
Preparation for 2008 Medicare/Medicaid bill including comparative effectiveness, issues related to the federal upper limit for Medicaid pharmacy reimbursement, Medicaid rebate, e-prescribing and Part D data disclosure issues (no bill introduced yet)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Agency for Health Care Policy & Research
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Richard |
Smith |
|
|
|
Ann |
Kaplan |
|
|
|
Lauryl |
Jackson |
|
|
|
Alan |
Gilbert |
|
|
|
Steve |
Tilton |
|
|
|
Amy |
Efantis |
|
Legislative Director - Rep. Artur Davis |
|
Bryant |
Hall |
|
|
|
Andrea |
Bergman |
|
|
|
Hallie |
Maranchick |
|
|
|
Heather |
Strawn |
|
|
|
Derrick |
White |
|
|
|
Michael |
Woody |
|
Professional Staff - Senate HELP Committee |
|
Billy |
Tauzin |
|
|
|
Mimi |
Kneuer |
|
|
|
Maya |
Bermingham |
|
|
|
Randy |
Burkholder |
|
|
|
Byron |
Patterson |
|
|
|
Marjorie |
Powell |
|
|
|
Lori |
Reilly |
|
|
|
Jennifer |
Van Meter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
H.R. 3920, Trade and Globalization Assistance Act of 2007: trade adjustment assistance issues
H.R. 5501, President's Emergency Plan For AIDS Relief (PEPFAR): intellectual property, access to medicines and public health
S. 1848, Trade and Globalization Adjustment Assistance Act of 2007: trade adjustment assistance issues
S.2731, President's Emergency Plan For AIDS Relief (PEPFAR): intellectual property, access to medicines and public health
Colombia Free Trade Agreement: intellectual property, market access and public health
Korea Free Trade Agreement: intellectual property, market access and public health
Implementation of Peru Free Trade Agreement: intellectual property, market access and public health
World Health Organization (WHO) Intergovernmental Working Group on Public Health, Innovation and Intellectual Property (IGWG): intellectual property, access and public health
International market access and intellectual property issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR), State - Dept of (DOS), Commerce - Dept of (DOC), Natl Security Council (NSC), Natl Economic Council (NEC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Toohey |
|
|
|
Robert |
Filippone |
|
|
|
Billy |
Tauzin |
|
|
|
Stephanie |
Lane |
|
|
|
Jeffrey |
May |
|
|
|
Byron |
Patterson |
|
|
|
Richard |
Kjeldgaard |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
19 |
|
||||||
2 |
|
20 |
|
||||||
3 |
|
21 |
|
||||||
4 |
|
22 |
|
||||||
5 |
|
23 |
|
||||||
6 |
|
24 |
|
||||||
7 |
|
25 |
|
||||||
8 |
|
26 |
|
||||||
9 |
|
27 |
|
||||||
10 |
|
28 |
|
||||||
11 |
|
29 |
|
||||||
12 |
|
30 |
|
||||||
13 |
|
31 |
|
||||||
14 |
|
32 |
|
||||||
15 |
|
33 |
|
||||||
16 |
|
34 |
|
||||||
17 |
|
35 |
|
||||||
18 |
|
36 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: http://www.phrma.org/about_phrma/member_company_list/members/
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 10 | 19 |
2 | 11 | 20 |
3 | 12 | 21 |
4 | 13 | 22 |
5 | 14 | 23 |
6 | 15 | 24 |
7 | 16 | 25 |
8 | 17 | 26 |
9 | 18 | 27 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 19 | 37 |
2 | 20 | 38 |
3 | 21 | 39 |
4 | 22 | 40 |
5 | 23 | 41 |
6 | 24 | 42 |
7 | 25 | 43 |
8 | 26 | 44 |
9 | 27 | 45 |
10 | 28 | 46 |
11 | 29 | 47 |
12 | 30 | 48 |
13 | 31 | 49 |
14 | 32 | 50 |
15 | 33 | 51 |
16 | 34 | 52 |
17 | 35 | 53 |
18 | 36 | 54 |